<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> in the Japanese Health Insurance System in 2007 </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: S-p53Ab was measured as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker in 154 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients, and the results were categorized by clinical and pathological variables </plain></SENT>
<SENT sid="2" pm="."><plain>We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: S-p53Ab was positive in 33.1% of the <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>The positive rate was significantly higher in patients with lymph nodes <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P = 0.025) and lymphatic invasion (P = 0.023) </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with <z:e sem="disease" ids="C0677947" disease_type="Neoplastic Process" abbrv="">stage I colorectal cancer</z:e>, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The approved kit for S-p53Ab testing was found to be an effective <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The positive rate of S-p53Ab was significantly higher in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> involvement of the lymphoid tissues </plain></SENT>
<SENT sid="8" pm="."><plain>The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with <z:e sem="disease" ids="C0677947" disease_type="Neoplastic Process" abbrv="">stage I colorectal cancer</z:e>, suggesting that the S-p53Ab is a useful <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker for patients with early-stage disease </plain></SENT>
</text></document>